Search results

Advanced therapies Investor Day – Novemner 2016

http://www.oxfordbiomedica.co.uk/videos/advanced-therapies-investor-day-%E2%80%93-novemner-2016

Analyst Presentation: Interim results for the six months ended 30 June 2017

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2017

Analyst conference call: Oxford BioMedica and Bioverativ Collaboration

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-bioverativ-collaboration

Analyst conference call: Preliminary results for the year ended 31 December 2017

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-preliminary-results-year-ended-31-december-2017

Analyst conference call: Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-conference-call-oxford-biomedica-and-axovant-sciences-enter-8425-million

Analyst Presentation: Interim results for the six months ended 30 June 2018

http://www.oxfordbiomedica.co.uk/webcasts-and-audios/analyst-presentation-interim-results-six-months-ended-30-june-2018

Pages